NOTE L: STOCK-BASED COMPENSATION PLANS

The Company has a long-term incentive program for directors, officers and employees. Under this program, the Company initially authorized four million shares of Company common stock for the grant of incentive stock options, nonqualified stock options, restricted stock awards, and retroactive stock appreciation rights. The long-term incentive program was amended effective May 25, 2011, May 14, 2014 and May 17, 2017 to authorize an additional 900,000 shares, 1,000,000 shares and 1,000,000 shares, respectively, for the grant of incentive stock options, nonqualified stock options, restricted stock awards, and retroactive stock appreciation rights. Effective May 18, 2022, a new plan was adopted by the Company’s shareholders that authorized 600,000 shares of Company common stock for the same purpose. As of December 31, 2025, the Company has authorization to grant up to approximately 0.9 million additional shares of Company common stock for these instruments.

Nonqualified Stock Options

The Company recognized stock-based compensation expense related to non-qualified stock options of $3.5 million, $2.7 million and $3.2 million for the years ended December 31, 2025, 2024 and 2023, respectively. A related income tax benefit was recognized of $0.9 million, $0.7 million and $0.8 million for the years ended December 31, 2025, 2024 and 2023, respectively.

The nonqualified (offset) stock options in the Director’s Stock Balance Plan vest and become exercisable immediately and expire one year after the date the director retires or two years in the event of death. The remaining options have a ten-year term, and vest and become exercisable on a grant-by-grant basis, ranging from immediate vesting to ratably over a five-year period.

Activity in this long-term incentive program is as follows:

Stock Options

Weighted-

average Exercise

  ​ ​ ​

Outstanding

  ​ ​ ​

Price of Shares

Outstanding at December 31, 2023

 

1,641,854

$

54.27

Granted

 

315,804

 

44.27

Exercised

 

(260,642)

 

41.45

Forfeited

 

(53,089)

 

56.41

Outstanding at December 31, 2024

 

1,643,927

54.31

Granted

 

277,480

 

58.10

Exercised

 

(140,219)

 

38.45

Forfeited

 

(22,894)

 

58.69

Outstanding at December 31, 2025

 

1,758,294

 

56.12

Exercisable at December 31, 2025

 

1,114,382

$

57.10

The following table summarizes the information about stock options outstanding under the Company’s stock option plan at December 31, 2025:

Options outstanding

Options exercisable

Weighted-

Weighted-

Weighted-

average

average

average

Exercise

Remaining

Exercise

Range of Exercise Price

  ​ ​ ​

Shares

  ​ ​ ​

Price

  ​ ​ ​

Life (years)

  ​ ​ ​

Shares

  ​ ​ ​

Price

$0.00 – $26.00

 

20,001

$

23.04

 

1.38

 

20,001

$

23.04

$36.01 – $46.00

 

385,579

 

42.67

 

6.13

 

171,440

 

40.67

$46.01 – $56.00

 

523,212

 

53.74

 

4.90

 

413,319

 

53.66

$56.01 – $81.00

 

829,502

 

64.66

 

5.81

 

509,622

 

66.81

TOTAL

 

1,758,294

$

56.12

 

5.56

 

1,114,382

$

57.10

The weighted-average remaining contractual term of outstanding and exercisable stock options at December 31, 2025 and 2024 is 5.56 years and 5.55 years, respectively. The aggregate intrinsic value of outstanding and exercisable stock options at December 31, 2025 and 2024 total $5.2 million and $9.9 million, respectively.

Management estimated the fair value of options granted using the Black-Scholes option-pricing model. This model was originally developed to estimate the fair value of exchange-traded equity options, which (unlike employee stock options) have no vesting period or transferability restrictions. As a result, the Black-Scholes model is not necessarily a precise indicator of the value of an option, but it is commonly used for this purpose. The Black-Scholes model requires several assumptions, which management developed based on historical trends and current market observations. Expected volatilities are based on historical volatilities of the Company’s common stock. The Company uses historical data to estimate option exercise and post-vesting termination behavior. The expected term of options granted is based on historical data and represents the period of time that options granted are expected to be outstanding, which takes into account that the options are not transferable. The risk-free interest rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of the grant.

  ​ ​ ​

2025

  ​ ​ ​

2024

  ​ ​ ​

2023

 

Weighted-average Fair Value of Options Granted

$

15.71

$

12.32

$

14.93

Assumptions:

 

 

 

Weighted-average expected life (in years)

 

6.50

 

6.50

 

6.50

Future dividend yield

 

2.94

%  

 

2.77

%  

 

2.48

%

Share price volatility

 

30.08

%  

 

29.95

%  

 

29.72

%

Weighted-average risk-free interest rate

 

4.18

%  

 

4.31

%  

 

3.74

%

Unrecognized stock-based compensation expense related to non-vested stock options totaled $7.3 million at December 31, 2025. The weighted-average period over which this unrecognized expense would be recognized is 3.3 years. The total fair value of stock options vested during 2025, 2024, and 2023 were $3.1 million, $3.4 million and $2.7 million, respectively.

During the 12 months ended December 31, 2025 and 2024, proceeds from stock option exercises totaled $4.8 million and $10.0 million, respectively, and the related tax benefits from exercise were approximately $0.5 million and $0.6 million, respectively. During the twelve months ended December 31, 2025 and 2024, approximately 0.1 million and 0.2 million shares, respectively, were issued in connection with stock option exercises each year. The total intrinsic value of options exercised during 2025, 2024 and 2023 were $3.1 million, $4.9 million and $1.7 million, respectively.

Restricted Stock Awards

Compensation expense is recognized over the vesting period of the awards based on the fair value of the Company’s stock at grant date. The amount of stock-based compensation expense related to restricted stock vesting recognized in the income statement for 2025, 2024 and 2023 was approximately $6.5 million, $5.6 million and $4.5 million, respectively.

The fair value of restricted stock awards is based on the end-of-day share price of the Company’s stock on the grant date. Restricted stock awards granted prior to 2022 vest ratably over a five-year period and restricted stock awards granted in 2022 and thereafter vest ratably over a three-year period. During the forfeiture period, shares that have not been forfeited have the right to vote and the right to receive dividends.

A summary of the status of the Company’s unvested restricted stock awards as of December 31, 2025, and changes during the twelve months ended December 31, 2025 and 2024, is presented below:

Restricted

Weighted-average

  ​ ​ ​

Shares

  ​ ​ ​

grant date fair value

Unvested at December 31, 2023

 

149,563

$

62.31

Awards

 

88,929

 

44.43

Forfeitures

 

(14,457)

 

61.68

Vestings

 

(78,279)

 

62.41

Unvested at December 31, 2024

 

145,756

51.43

Awards

 

81,940

 

57.99

Forfeitures

 

(3,310)

 

53.06

Vestings

 

(76,051)

 

54.28

Unvested at December 31, 2025

 

148,335

$

53.56

Unrecognized stock-based compensation expense related to unvested restricted stock totaled $4.7 million at December 31, 2025, which will be recognized as expense over the next three or five years according to the awards vesting schedule. The weighted-average period over which this unrecognized expense would be recognized is 1.8 years. The total fair value of restricted stock vested during 2025, 2024, and 2023 were $4.1 million, $4.9 million and $3.4 million, respectively.

Performance Awards

The long-term incentive program provides for the issuance of shares of performance award restricted stock to officers and key employees. There are two sets of performance criteria based on the individual award; (1) based on the Company’s cumulative three year Relative Total Shareholder Return (“TSR”) ranking compared to the constituents of the KBW Regional Bank Index, and continued employment weighted at 50%; and (2) three year Average Relative Return on Average Core Tangible Common Equity (“Core ROATCE”) Relative Total Performance Goal weighted at 50%. Compensation expense is recognized over the vesting period of the awards based on the fair value of the stock at issue date. Management estimated the fair value of the stock granted under performance criteria using the Monte Carlo Simulation and stock granted under the market criteria using the grant date fair value. Performance shares cliff vest based on performance results for a three-year period. Compensation cost is estimated based on the probability that the performance and market conditions will be achieved. As of December 31, 2025, the compensation cost is estimated at 57% payout under the terms of the plan for the different performance sets. At each reporting period, the Company will reassess the likelihood of achieving the performance criteria and will adjust compensation expense as needed. The shares have voting rights. Upon vesting of the performance shares, any dividends declared during the vesting period will be paid based on the shares vested. Total shares issuable under the plan are 124,478 at December 31, 2025 with 52,132 shares issued in 2025 and 60,358 shares issued in 2024.

Performance

Restricted 

Weighted-average 

  ​ ​ ​

 Shares

  ​ ​ ​

grant date fair value

Unvested at December 31, 2023

 

81,138

$

27.15

Awards

 

60,358

 

21.32

Forfeitures

 

(25,139)

 

29.54

Vestings

 

(7,483)

 

31.31

Unvested at December 31, 2024

 

108,874

25.02

Awards

 

52,132

 

29.93

Forfeitures

 

(21,589)

 

29.31

Vestings

 

(14,939)

 

30.52

Unvested at December 31, 2025

 

124,478

$

25.67

Unrecognized stock-based compensation expense related to unvested performance restricted stock totaled $2.3 million at December 31, 2025, which will be recognized as expense over the next three years. The weighted-average period over which this unrecognized expense would be recognized is 1.6 years. The total fair value of performance restricted stock vested during 2025 was $0.4 million, and was $0.2 million and immaterial in 2024 and 2023, respectively.

Historical Timeline

Fiscal YearFiled
2025Feb 27, 2026Showing above
2022Mar 1, 2023
2021Mar 1, 2022
2020Mar 1, 2021
2019Mar 2, 2020
2018Mar 1, 2019

About Stock Compensation Disclosures

Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.

Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.